Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) was the target of a significant decline in short interest in August. As of August 14th, there was short interest totaling 140 shares, a decline of 91.3% from the July 30th total of 1,608 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 1,984 shares, the short-interest ratio is presently 0.1 days.

Mosaic ImmunoEngineering Stock Performance

Shares of OTCMKTS CPMV opened at $0.06 on Wednesday. Mosaic ImmunoEngineering has a 12 month low of $0.05 and a 12 month high of $1.05. The firm has a market capitalization of $441,640.00, a PE ratio of -0.68 and a beta of -0.82. The firm has a fifty day simple moving average of $0.49 and a two-hundred day simple moving average of $0.57.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last posted its earnings results on Friday, August 14th. The company reported ($0.02) EPS for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.